Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Kilitch Drugs India Ltd - 524500 - Outcome Of Board Meeting - Financial Results For The Quarter And Year Ended 31St March, 2021

 We enclosed herewith the audited standalone and consolidated financial results of the Company for the quarter and year ended 31st March, 2021, which have been approved and taken on record at the meeting of the Board of Directors of the Company held today, i.e. 22nd June, 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we would like to confirm that M/s. A.M. Ghelani & Co., Chartered Accountants (Firm Registration no. 103173W)), Statutory Auditors of the Company, have issued Audit Reports with unmodified opinion on the above financial results. The meeting of Board of Directors held today commenced at 4:00 PM and concluded at 5:35 PM.
22-06-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for Intimation Of Board Meeting For The Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2021

 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/06/2021 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Result of the Company for the quarter and financial year ended 31st March 2021;
15-06-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we are forwarding herewith the Annual Secretarial Compliance Report for the financial year 2020-21.
07-06-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 We wish to inform you that pursuant to Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company considered and approved the allotment of 67,470 Equity Shares of Rs. 10 each on 30 April, 2021 pursuant to exercise of options granted to employees of the Company under ESOS Scheme.
30-04-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Dear Sir/ Madam, Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, please find enclosed intimation received from our Registrar and Share Transfer Agent - Link Intime India Private Limited providing information regarding loss of share certificates by shareholder/s.
29-04-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayKILITCH DRUGS (INDIA) LTD. 2CINL24239MH1992PLC066718 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Garima Trivedi Designation: Company Secretary EmailId: garimatrivedi@kilitch.com Name of the Chief Financial Officer: Sunil Jain Designation: Chief Financial Officer EmailId: suniljain@kilitch.com Date: 28/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015

 Please find enclosed Compliance Certificate pursuant to the Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2021.
20-04-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholding for the Period Ended March 31, 2021

 Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
19-04-2021
Bigul

Kilitch Drugs India Ltd - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018.This is for your information and records.
19-04-2021
Bigul

KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended March 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Mukund MehtaDesignation :- Managing Director / Whole Time Director
19-04-2021
Next Page
Close

Let's Open Free Demat Account